Anlotinib Combined With S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial

Asian Pacific Journal of Cancer Prevention
doi 10.31557/apjcp.2019.20.12.3849
Full Text
Abstract

Available in full text

Date
Authors
Publisher

EpiSmart Science Vector Ltd

Related search

Durvalumab in Frail and Elderly Patients With Stage Four Non-Small Cell Lung Cancer: Study Protocol of the Randomized Phase II DURATION Trial

Trials
MedicinePharmacology
2020English

Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-Ii Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Erlotinib Treatment in Pretreated Patients With Non-Small Cell Lung Cancer: A Phase II Study

Oncology Letters
Cancer ResearchOncology
2010English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients With Extensive-Stage Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2009English

Safety and Effectiveness of Localized Lung Resection Combined With Neoadjuvant Chemotherapy in the Treatment of Stage I-Ii Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2017English

Image Features for the Future in Stage IV Non-Small Cell Lung Cancer

English

Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy